Asia Scientific Global (ASG), a leader in the research and development of novel inhaled drugs, has set up a laboratory in Taiwan, and plans to establish a second facility in Singapore later this year. This new lab will focus on developing 505(b)2 new dosage form drugs targeting four key areas: antibiotics, erectile dysfunction, respiratory health, and the central nervous system.

ASG revealed that Beta1, a novel drug currently under development, has successfully completed toxicology testing. The drug is slated to undergo a series of international multicenter clinical trials from 2024 to 2026.

Additionally, the company intends to establish offices and local teams in China, Southeast Asia, and North America, integrating the planning processes for new product development, clinical trials, and market expansion. By leveraging Asia as its new R&D hub, ASG is expanding globally and expediting the clinical trial processes for its novel medicines.

With the strategic goal of licensing its products to international pharmaceutical companies, ASG is actively seeking partners to expedite the development and commercialisation of its drugs. ASG's drug development platform technology, along with its drug formulations and preparation methods, are currently pending US patent approval.